Esperion Therapeutics Inc (ESPR)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014041)
◆英語タイトル:Esperion Therapeutics Inc (ESPR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014041
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:49
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Esperion Therapeutics Inc (Esperion) is a pharmaceutical company that develops and commercializes oral therapies to treat patients with elevated low-density lipoprotein cholesterol (LDL-C). The company’s lead product candidate, Bempedoic acid, an ATP-citrate lyase inhibitor which is in Phase 3 clinical development that reduces elevated LDL-C levels in patients with hypercholesterolemia. It also focuses on the development of bempedoic acid in a fixed dose combination with ezetimibe, an LDL-C lowering therapy. Esperion is headquartered in Ann Arbor, Michigan, the US.

Esperion Therapeutics Inc (ESPR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Esperion Therapeutics Acquires 4WF from Cleveland Clinic 11
Venture Financing 12
Esperion Therapeutics Raises US$33 Million In Venture Financing 12
Esperion Therapeutics Raises US$1 Million In Venture Financing 14
Equity Offering 15
Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 15
Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 17
Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 19
Esperion Therapeutics Completes Underwriters’ Exercise Of Over-Allotment Option For IPO For US$70 Million 21
Esperion Therapeutics Inc – Key Competitors 23
Esperion Therapeutics Inc – Key Employees 24
Esperion Therapeutics Inc – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Financial Announcements 26
Nov 07, 2017: Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results 26
Aug 08, 2017: Esperion Reports Second Quarter 2017 Financial Results 28
May 04, 2017: Esperion Reports First Quarter 2017 Financial Results 29
May 04, 2017: Esperion Therapeutics Q1 net loss up 30
Nov 03, 2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financial Results 31
Aug 04, 2016: Esperion Therapeutics Reports Second Quarter 2016 Financial Results 33
May 04, 2016: Esperion Therapeutics Reports First Quarter 2016 Financial Results 34
Feb 25, 2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2015 Financial Results 35
Corporate Communications 37
Aug 11, 2017: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 37
Product News 39
08/04/2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Update 39
05/04/2016: Esperion Therapeutics Provides Bempedoic Acid Development Program Updates 40
Product Approvals 42
Jun 26, 2017: Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and Ezetimibe 42
Clinical Trials 43
Nov 06, 2017: Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill 43
Aug 08, 2017: Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin 44
Jun 28, 2016: Esperion Therapeutics Provides Clinical Development and Regulatory Update for Bempedoic Acid 45
Jan 13, 2016: Esperion Therapeutics Announces Initiation of Phase 3 Clinical Program With Long-Term Safety and Tolerability Study 47
Jan 12, 2016: Esperion Therapeutics Announces Initiation of Phase 2 Clinical Study of Bempedoic Acid in Patients Treated With High-Dose Statin Therapy 48
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Esperion Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Esperion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Esperion Therapeutics Acquires 4WF from Cleveland Clinic 11
Esperion Therapeutics Raises US$33 Million In Venture Financing 12
Esperion Therapeutics Raises US$1 Million In Venture Financing 14
Esperion Therapeutics Prices Public Offering of Shares for USD152 Million 15
Esperion Therapeutics Raises USD201 Million in Public Offering of Shares 17
Esperion Therapeutics Raises USD98 Million in Public Offering of Shares 19
Esperion Therapeutics Completes Underwriters' Exercise Of Over-Allotment Option For IPO For US$70 Million 21
Esperion Therapeutics Inc, Key Competitors 23
Esperion Therapeutics Inc, Key Employees 24

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Esperion Therapeutics Inc (ESPR)-製薬・医療分野:企業M&A・提携分析(Esperion Therapeutics Inc (ESPR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆